Abhivandan Nagia’s Post

Pitt Street Research publishes an initiation report on Dimerix Limited - a clinical stage drug developer which is developing DMX-200 for kidney diseases. DMX-200 is in a Phase 3 trial for FSGS (Focal Segmental Glomerulosclerosis) and has completed a Phase 2 study for diabetic kidney disease. The company is expecting initial analysis in mid-March and could submit for conditional marketing approval in CY24, subject to successful results. It has secured a licensing deal with Advanz Pharma that could bring A$230m in milestone payments, plus royalties on sales. Notwithstanding all this, it is still priced like a Phase 2 company - we value DXB was A$0.58 per share in our base case scenario and A$0.77 in our bull case scenario, equating to equity values of A$246.3m and A$326.3m which are more in line with the valuation of ASX biotechs at Phase 3. Please be advised that this report is General Advice only and is a report commissioned by the Company. Please see p.20 for the key risks and the final page for the full General Advice Warning, disclosures and disclaimers. Marc Kennis Stuart Roberts Mark Diamond Nina Webster Hugh Alsop Clinton Snow Sonia Poli Hamish George #dimerix #dxb200 #kidneyhealth #kidneydisease #biotech #biotechs #biotechstocks #healthstocks #ASX #equities #equityresearch #researchreport #researchinitiation https://lnkd.in/eyjWtZ8T

🟢 Don't miss out! Our promotion for 15% off our full-length proteins and antibodies ends on February 15! 🟢 Did you know that around 60% of drugs target transmembrane proteins? However, challenges like low expression and purification issues have limited their use. Sino Biological is at the forefront, addressing these challenges. With a focus on multi-pass transmembrane proteins, we've established three innovative platforms – virus-like particles (VLP), detergent micelle, and nanodisc – providing key materials for early-stage drug development. Check out our custom services and range of multipass transmembrane proteins offered, including GPCRs (GPRC5D, CXCR4, SSTR2, CB2), Claudins, and more. https://ow.ly/sNcQ50QysTu #DrugDevelopment #TransmembraneProteins #Promotion

Top 12 Most Popular Drug Hunter Case Studies of 2023 | https://lnkd.in/eKMeqqqK 2023 was an incredible year in drug discovery, with many remarkable case studies on challenging targets like KRAS, programs employing emerging modalities like degraders or oral macrocyclic peptides, and compounds with fascinating properties like allostery and mutant-selectivity. Check out the top 12 most popular case studies published in 2023 here: Full list: https://lnkd.in/eKMeqqqK

Find targets for typically ‘difficult to drug’ binding pockets, by using Spark’s ‘Macrocyclization’ experiments within your drug discovery projects. Macrocyclic compounds can present several advantages such as: ✨ Diverse functionality ✨ Favorable drug-like properties ✨ Increased selectivity Find out how to drug difficult binding pockets using ligand macrocyclization: https://lnkd.in/ekGTKmjG #DMTA #drugdiscovery #drugdesign #computationalchemistry #compchem #medicinalchemistry #medchem #CADD #cheminformatics

Save the date for the next #MedChemCASES

📢 Rebooting the "Small Molecule Highlights" Series! 🚀 Excited to announce the revival of our well-received blog series after a rejuvenating summer hiatus. Immerse yourself in fresh insights from 6 carefully selected small molecules, thoughtfully curated from the latest drug discovery literature. Allow us to introduce our new voice, 👨🔬David Rosa, Ph.D., Senior Scientist at Dalriada Drug Discovery. These compounds are aimed at diverse targets - DLK, FXR, FLT3, AR, PKM2, and AcrAB-TolC. Dive into the full article here➡️https://lnkd.in/gM69b6xr #medicinalchemistry #drugdesign #drugdiscovery #drughunter #pharma #biotech #healthcare #medicine #pharmacology #smallmolecules

Learn how your peers are discovering new treatment modalities when utilizing our newest patented technology (Spectral Shift) combined with Microscale Thermophoresis (MST) #drugdiscovery , #drugdevelopment , #proteinengineering .

Are you interested in learning how to identify and optimize compounds that can bind to difficult-to-drug pockets, or do you want to discover the hidden potential of macrocyclic compounds in your drug discovery projects?   If yes, Explore Spark’s ‘Macrocyclization’ experiments within your drug discovery projects.   Read the article https://lnkd.in/ekGTKmjG, to know more about how to drug difficult binding pockets using Spark’s ‘Macrocyclization’ experiments and learn several advantages Macrocyclic compounds can present in your discovery projects. #DMTA #drugdiscovery #drugdesign #computationalchemistry #compchem #medicinalchemistry #medchem #CADD #cheminformatics #Spark #macrocyclization

Thoughts on this? >> Pathios rakes in $25M to help start trials for GPR65 inhibitor >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #biotech #pharmaceutical #healthcare #pharma

Two excellent bioprocessing topics from #acsbiot. Register today!